Loading
Fluid taken from the lower back contains DNA from brain tumours. Testing it can diagnose, monitor and detect resistance without brain surgery.
Cerebrospinal fluid ctDNA outperforms plasma for central nervous system tumours and detects leptomeningeal disease earlier than cytology or MRI in several studies, including paediatric brain tumours and lymphoma. Standardisation, assay validation and demonstrating that acting on the result improves outcomes are the missing pieces.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares The brain: barrier and sanctuary, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.